Skip to content

ACCELERATING THE NEXT GENERATION OF PROCESS DEVELOPMENT & MANUFACTURING FOR THE UK

3-4 November 2026 Radisson Blu Hotel, London Heathrow, London, United Kingdom
Co-located Events
BFL2026_logo_square_white 2
BioSourceEurope2026 logo white

KEY THEMES & TOPICS

Biologics Manufacturing Strategy
Next-Gen Upstream Processing
Downstream Purification Optimisation
AI & Data Analytics for Process Robustness
Building Future-Ready Biomanufacturing Capacity
Supply Chain Resilience and Logistics
WHO
 For Site Heads, Manufacturing VPs, and Engineering Directorsbased in the UK & Ireland, or global firms investing in the region's capacity. 
WHAT
  The premier operational gathering for the UK/IE biopharma hub, focusing on MHRA regulatory innovation, digital transformation, and capacity expansion. 
WHY
 To leverage the UK’s unique Point-of-Care framework and Ireland’s massive infrastructure growth to build a "Western Launchpad" for global biologics.  
icons cgw welcome_1
0 +

Senior Attendees

Meet a concentrated audience of Site Heads, Manufacturing VPs, and Engineering Directors from the UK & Ireland’s top biopharma hubs and investment projects. 
icons cgw welcome-02
0 +

Expert Speakers

Hear from world-class leaders in regulatory innovation (MHRA), facility design, digital manufacturing, and workforce development for the next generation of biologics. 
bwd2026-company-ezgifcom-speed.bb78342dfc94
0 +

Companies Represented

A gathering representing major global pharma investors, UK innovators, leading engineering firms, and technology providers building the future of British bioproduction. 

AGENDA AT A GLANCE

Day 1 | 3 November 2026
Biologics Manufacturing Strategy
Networking Break
Optimising CDMO Partnerships and Technical Transfer
 Spotlight: ADC Outsourcing Excellence
Lunch
Next-Gen Upstream Processing
Downstream Purification Optimisation
Networking Break
Strategies For Selecting & Managing CDMOs
Industry Roundtables
End of Conference Day 1
Day 2 | 4 November 2026
Managing Quality Oversight Across External Manufacturing Networks
Networking Break
AI & Data Analytics for Process Robustness
Lunch
Building Future-Ready Biomanufacturing Capacity
Supply Chain Resilience and Logistics
Panel Discussion - The Future of Biopharma Supply Chains – Building Resilience, Agility & Sustainability
Networking Break
Closing Panel Discussion – Future of European Biomanufacturing
End of Conference
DAY 1
3 November 2026
VIEW DAY 1 VIEW DAY 2
08:00 Registration & Coffee
08:50

Chairman’s Welcome Address

Dr Uwe Gottschalk Operating Partner, Keensight Capital, France
Biologics Manufacturing Strategy
09:00

Supply Chain Decision Intelligence – Increasing the Volume & Velocity of Decisions

  • Leveraging real-time data analytics to improve visibility across end-to-end biologics supply networks
  • Using AI-driven forecasting to accelerate decision-making on demand shifts, capacity, and inventory
  • Integrating cross-functional data streams to reduce bottlenecks and improve responsiveness
  • Enhancing risk detection and scenario planning to support faster, more confident supply chain decisions

 

Niveth Richard Supply Chain Decision Intelligence Lead, GSK, UK
09:25

Architecture Control of Lipid Nanoparticles Enabled by Process Analytics

  • Size, Morphology control of lipid nanoparticles
  • Automated process development platform enabled by inline DLS measurements
  • Preserving lipid nanoparticle architecture from development to manufacturing scale
Solution Provider
Peter Sagmeister Co-Founder, BIZON Labs, Austria
09:50

Biologics manufacturing Fit for Future - managing more complex molecules and a diverse product range

  • Changing from fewer, larger products to smaller  
  • Besides reliability and quality increase flexibility in the organization 
  • Improve installations with limited changes for new or non-standard products 
  • Use AI and mulitavariant analysis to use the data to have the best impact 
Dirk Boehm Site Head DS Penzberg (VP), Roche, Germany
10:15

Accelerate mAb & ADC developability and LNP workflows with Unchained Labs

  • AI-Powered Biologics Characterisation: Leveraging large biophysical datasets to assess protein, antibody and conjugate developability.

  • High-Throughput Analytics: Simplifying complex, labour-intensive testing through low-volume biologics analysis and the AI Developability Workcell.
  • End-to-End Nanoparticle Development: Supporting nucleic acid payload screening, encapsulation, formulation optimisation and process development.
  • Scalable LNP Workflows: Using the Sunny suite to transition seamlessly from early-stage research to GMP-scale production.
  • Integrated Analytical Solutions: Ensuring consistency, efficiency and scalability across nanoparticle development workflows
Solution Provider
Andre Mueller Director of Product Management, Unchained Labs, USA
10:40 Networking Break
Optimising CDMO Partnerships and Technical Transfer
11:10

Building Faster, Smarter and More Predictable Technology Transfers with Digital Intelligence

  • Building a trusted CMC data foundation as the backbone for faster, more reliable transfers

  • Connecting AI, automation and digital tools across the end-to-end technology-transfer process

  • Translating digital insights into manufacturing readiness, reduced risk and fewer pre-PPQ runs

  • Establishing measurable standards for value tracking, acceleration and continuous improvement

  • Scaling a repeatable approach across products, modalities, sites and partnerships

Filippo Ramondelli Associate Director - TT & Project Management Lead, Takeda, Italy
11:35

Supporting ADC From IND To The Long Term Commercial Supply: A Step Ahead Against The Challenges Of The Bioconjugates

  • Serving the Innovators from the candidate selection to the IND, from Phase I to the long term commercial supply
  • Driving ADC Success with Flexible & High-Quality Solutions from Preclinical to Commercial
  • Highlights on the approach to support early stage program through robust development studies.
  • Ensuring right first-time-approved regulatory submission to save time and costs.
Solution Provider
Giorgio Salciarini Head of Sales - Technical Business Development, BSP Pharmaceuticals, Italy
12:00

De-Risking Tech Transfer and Scale-Up of New manufacturing Processes

  • Managing successful tech transfer across complex manufacturing processes  
  • Reducing scale-up risks while maintaining product quality and consistency  
  • Improving communication and operational alignment between operations and development  
  • Managing project lifecycle and continuous improvement 
Anthony Beaney Principal Scientist, Lonza Biologics, UK
12:30 Lunch
Next-Gen Upstream Processing: Intensification & Perfusion
13:30

Unlocking Biologics Manufacturing Potential: Case Studies in Data Science Applications

  • Applying data science to optimize upstream and downstream process performance and reduce variability
  • Using advanced analytics to identify root causes of batch deviations and improve yield consistency
  • Leveraging predictive models to enhance process control, scale-up success, and tech transfer efficiency
  • Demonstrating real-world case studies where data-driven insights improved cost, quality, and time-to-market
Shyam Panjwani Senior Principal CMC Data Scientist, Bayer, USA
13:55

Glutenase at Scale: Where Process Development Meets Sustainability

  • Scalable Process: Developing a cost-efficient, sustainable manufacturing process for TAK-062.
  • Process Optimisation: Targeting resource-intensive steps through innovative technologies.
  • Key Improvements: Antibiotic-free fermentation, raw material optimisation, and waste reduction.
  • Scale-Up: Integrating yield enhancement and process intensification for commercial production.
Michael Palige Process Development & CMC Lead, Takeda, Austria
Downstream Purification Optimisation
14:20

Bispecific Purification: Double Trouble or Twice as Nice?

  • Tackling complex product-related impurities in bispecific purification
  • Impact of molecular design, clone selection and analytics on manufacturability
  • Developing robust, scalable purification strategies for next-generation bispecifics
  • Industrial case studies and key lessons learned
Gavin Wild Head of Early Process Sciences, UCB, UK
14:45 Networking Break
Strategies for Selecting & Managing CDMOs
15:00

Partnering for Success: Integrating Internal Expertise with External Manufacturing Capabilities

  • CDMO selection process, relationship management
  • An example of what can be achieved when both parties are aligned on a shared vision.
Franz Schnetzinger VP / Head PAD & QC, AAVantgarde Bio, UK
15:25

Managing CDMO Partnerships Across Formulation & Clinical Trial Supply Networks

  • Selecting the right CDMO partners for formulation development, manufacturing, and commercial supply.
  • Establishing governance models that drive performance, transparency, and long-term collaboration.
  • Managing supply chain risks, capacity constraints, and business continuity across external networks.
  • Using performance metrics and operational reviews to ensure quality, reliability, and on-time delivery.
Karen O'Hanlon Chief Operating Officer, StablePharma, UK
15:50

Choosing the Right Outsourcing Partner: From Payload to Fill-Finish

  • Strategic partner selection for long-term external manufacturing success
  • Building strong governance frameworks across global CDMO partnerships
  • Strengthening supply resilience and managing operational risk
  • Driving performance oversight from development through commercial supply
Abisola (Abi) Kuforiji Associate Director-External Manufacturing -Operations lead (EMEA), MSD, Switzerland
16:05
Roundtable Discussion

AI in Supply Chain - Are they dependable for decisions?

Niveth Richard Supply Chain Decision Intelligence Lead, GSK, UK

Scaling Biologics Manufacturing for Future Demand

Dirk Boehm Site Head DS Penzberg (VP), Roche, Germany

Maximising Drug Product Manufacturing

Alexander Hempel Director Manufacturing, Avethera, Germany

Securing Biomanufacturing Supply Chains: Innovative Approaches to Accessing Critical Materials and Consumables (LMICs approach)

Valerie Chambard-Benalleg Manufacturing Supply Chain Lead, CEPI, UK

The Outsourcing Paradox: Preserving bandwidth without losing scientific expertise and strategic control.

Julia Hinteramskogler Head of Technical Development, Elaris, Austria

Building High-Trust Sponsor-CDMO Relationships

Franz Schnetzinger VP / Head PAD & QC, AAVantgarde Bio, UK

Formulation as a Commercial Differentiator

Marco Carfagna Head of Formulation Development & Drug Product Labs, Formycon, Germany
17:20 Key Takeaways
17:05 Cocktail Reception
18:00 End of Conference Day 1
DAY 2
4 November 2026
VIEW DAY 1 VIEW DAY 2
08:00 Registration & Coffee
08:50

Chairman’s Welcome Address

Dr Uwe Gottschalk Operating Partner, Keensight Capital, France
Managing Quality Oversight Across External Manufacturing Network
09:00

Building Robust Quality Governance Across Global CDMO Networks

  • Establishing effective quality governance frameworks across global CDMO networks
  • Strengthening sponsor–CDMO collaboration through clear accountability, communication, and oversight
  • Implementing risk-based approaches to supplier management, audits, and quality performance monitoring
  • Maintaining inspection readiness and consistent GMP compliance across outsourced manufacturing operations
Marcelo Castro Senior Director, Global Biopharma External Supply Operations Quality, Pfizer, Ireland
09:25

Enhancing Visibility and Control in External Manufacturing Quality Systems

  • Strengthening quality oversight across complex external manufacturing networks
  • Improving real-time visibility and risk management within supplier quality systems
  • Aligning sponsor–CDMO quality expectations and governance frameworks
  • Leveraging digital tools and data analytics to enhance compliance and operational control
Cathal Gallagher Senior Director-Head of Quality, External Operations EU, Takeda, Ireland
09:50

Speed to Clinic: Tech Transfer and Phase I Manufacturing in Under 6 Months 

Solution Provider
Dr Ashwinkumar V Meru Head of Global Business Development, Kemwell, India
10:15

Strengthening Quality Oversight Across External Manufacturing Networks

  • Standardising GMP and quality systems across CDMO partners for consistent compliance
  • Using digital QMS tools for real-time deviation tracking and faster resolution
  • Strengthening risk-based audits and supplier qualification across sites
  • Driving continuous improvement through CAPA and shared quality KPIs
Jose Martinez Calderon QA R&D and Commercial Product Development Senior Director, Almirall, Spain
10:40 Networking Break
AI & Data Analytics for Process Robustness
11:10

From Data Rich To Decision Intelligent

  • Establishing effective governance frameworks for AI and data across manufacturing and supply chain functions
  • Aligning AI and data strategies with business priorities, operational needs and measurable outcomes
  • Balancing data quality, accessibility, security and compliance to enable trusted AI adoption
  • Moving from individual AI use cases to scalable, cross-functional digital transformation and value creation 
Syed Saqib Naqvi Senior Manager, Digital Excellence, Amicus Therapeutics, UK
11:35

Single Cell Analysis for Enhanced Characterisation

  • Leveraging single-cell analysis for deeper product and process characterisation
  • Identifying cell-to-cell variability and critical subpopulations
  • Linking cellular attributes to productivity and product quality
  • Supporting better clone selection and process optimisation
Dr Aurelien Bunga Senior Scientist, Rinri Therapeutics, UK
12:00

Beyond the Straight Line: Kinetic Modelling for Faster, Defensible Stability Decisions

  • How advanced kinetic modelling (AKM) predicts long-term stability and shelf life from accelerated and stress data - reducing the real-time data needed to support a claim from years to months
  • Applying one modelling framework across the decisions biomanufacturers actually face: shelf-life determination, temperature-excursion assessment, and internal release limit setting
  • Quantifying uncertainty explicitly through prediction bands, rather than assuming it - producing outputs that stand up to regulatory scrutiny
  • Why AKM aligns with the direction of the evolving ICH Q1 guidance on model-informed stability strategies.
Dr Warren Roche Senior Biostatistician Expert, Argenx, Belgium
12:25 Lunch
Building Future-Ready Biomanufacturing Capacity
13:30

From Design to Manufacture: Developing CARKey, a New Generation of Programmable CAR-T Therapy

  • Programmable CAR-T design for greater precision and flexibility  
  • Translating CARKey from design to scalable manufacture  
  • Optimising CMC, quality and process consistency  
  • Advancing next-generation CAR-T towards clinical application 
Dr John Bridgeman Chief Scientific Officer, ImmunoKey, UK
13:55

Vaccine manufacturing networks in Low- and Middle-Income Countries

  • Strengthening regional vaccine manufacturing capacity and supply resilience in LMICs
  • Building sustainable technology transfer and local manufacturing partnerships
  • Overcoming infrastructure, workforce, and regulatory challenges across emerging markets
  • Enhancing equitable access through scalable and future-ready vaccine manufacturing networks
Vishal Mukund Sonje Senior Vaccine Manufacturing Lead, CEPI, UK
Supply Chain Resilience and Logistics
14:15

CEPI: An Input Materials Supply Organization for African Vaccine Input Material A Supply Consortium Model: Scope, Governance and Investment

  • Aggregating demand for critical vaccine input materials and consumables
  • Defining the scope of an African supply consortium model
  • Establishing governance structures and stakeholder responsibilities
  • Exploring investment needs and long-term sustainability
Valerie Chambard-Benalleg Manufacturing Supply Chain Lead, CEPI, UK
14:40 Networking Break
14:55
Panel Discussion

The Future of Biopharma Supply Chains – Building Resilience, Agility & Sustainability

  • Resilience in an Increasingly Unpredictable World  
  • Data, AI & Digitalisation – Creating a More Intelligent Supply Chain 
  • From Development to Launch – Building Supply Readiness Earlier 
  • Building the Future Supply Chain – Scalability, Sustainability & Patient Access 
Moderator
Dr Christopher van der Walle Head of Formulation Science, MHRA, UK
Panellists
Brendan Noone Senior Director, Global Supply Chain & Strategy, AstraZeneca, Ireland Shyam Panjwani Senior Principal CMC Data Scientist, Bayer, USA Max Corbett Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland Kellen LaVigne Director, Supply Chain & Logistics, Aurion Biotech, USA Kristin Grande Senior Manager, Technical Marketing - Life Sciences, Greenfield Global, USA
15:40
Panel Discussion

The Future of European Biomanufacturing: Capabilities, Competitiveness and Innovation

  • Biomanufacturing Beyond 2030: Future priorities and preparedness gaps
  • Europe’s Competitive Edge: Attracting development and manufacturing investment
  • Strategic Partnerships: Enabling scale-up while retaining critical in-house expertise
  • AI in Biomanufacturing: Opportunities, risks and implementation readiness
Moderator
Julia Hinteramskogler Head of Technical Development, Elaris, Austria
Panellists
Jose Martinez Calderon QA R&D and Commercial Product Development Senior Director, Almirall, Spain Syed Saqib Naqvi Senior Manager, Digital Excellence, Amicus Therapeutics, UK Michael Palige Process Development & CMC Lead, Takeda, Austria
16:15 Closing Remarks
16:45 End of Conference

MEET THE SPEAKERS

Filippo Ramondelli BIG PHARMA

Filippo Ramondelli

Associate Director - TT & Project Management Lead
Takeda
Italy
Connect on LinkedIn
Marcelo Castro BIG PHARMA

Marcelo Castro

Senior Director, Global Biopharma External Supply Operations Quality
Pfizer
Ireland
Connect on LinkedIn
Paul de Goede BIG PHARMA

Paul de Goede

Principal Scientist Formulation Development
Johnson & Johnson Innovative Medicine
Netherlands
Connect on LinkedIn
Tarik Cheema BIG PHARMA

Tarik Cheema

Asset Excellence Lead Pre-Filled Syringes
Roche
Switzerland
Connect on LinkedIn
Marieta Duvnjak BIG PHARMA

Marieta Duvnjak

Head Science & Operations in Analytical Research and Development
Novartis
India
Connect on LinkedIn
Max Corbett BIG PHARMA

Max Corbett

Senior Director, CMC Group Head Biologics and Small Molecule
CSL
Switzerland
Connect on LinkedIn
Sarah Pasqualinotto BIG PHARMA CHAIRMAN

Sarah Pasqualinotto

External Site Lead, External Operations (Associate Director)
Biogen
Switzerland
Connect on LinkedIn
Brendan Noone BIG PHARMA

Brendan Noone

Senior Director, Global Supply Chain & Strategy
AstraZeneca
Ireland
Connect on LinkedIn
BioUK2026_SPEAKER_Cathal Gallagher-1 BIG PHARMA

Cathal Gallagher

Senior Director-Head of Quality, External Operations EU
Takeda
Ireland
Connect on LinkedIn
BioUK2026_SPEAKER_Abisola (Abi) Kuforiji BIG PHARMA

Abisola (Abi) Kuforiji

Associate Director-External Manufacturing -Operations lead (EMEA)
MSD
Switzerland
Connect on LinkedIn
Sébastien Dasnoy

Sébastien Dasnoy

Principal Scientist, Injectable Formulation Development
UCB
Belgium
Connect on LinkedIn
Jose Martinez Calderon

Jose Martinez Calderon

QA R&D and Commercial Product Development Senior Director
Almirall
Spain
Connect on LinkedIn
Marco Carfagna

Marco Carfagna

Head of Formulation Development & Drug Product Labs
Formycon
Germany
Connect on LinkedIn
Harsha Reddy

Harsha Reddy

Group Lead - Head Upstream Process Development, CMC Bioprocess Lead
Accord BioPharma
UK
Connect on LinkedIn
Speakers_photo_foleon_Giorgio Salciarini

Giorgio Salciarini

Head of Sales - Technical Business Development
BSP Pharmaceuticals
Italy
Connect on LinkedIn
BioUK2026_SPEAKER_Kristin Grande-1

Kristin Grande

Senior Manager, Technical Marketing - Life Sciences
Greenfield Global
USA
Connect on LinkedIn

 Interested in Sharing Your Expertise and Insights? 

Sponsors & Media Partner

Special thanks to our event partners, without whom we would not be able to provide
this networking, learning, and collaborating platform to the community

Looking to partner with us for this event?

EXPECTED AUDIENCE SNAPSHOT
Biopharma (Mid-size & Emerging)
Attendance from

Biopharma (Mid-size & Emerging)

40%
Big Pharma
Attendance from

Big Pharma

25%
CDMO / CMO
Attendance from

CDMO / CMO

15%
Technology / Equipment / Solutions Providers
Attendance from

Technology / Equipment / Solutions Providers

15%
Academia / Research / Government
Attendance from

Academia / Research / Government

5%

Decision Makers

C-Suite / EVP (CEO, COO, CSO)
VP / Global Head / Site Head
Director / Associate Director
Senior Manager / Manager
Business Development

By Geography

BioManuUK2026-map

By Job Function

Manufacturing Operations / Site Leadership
0%
MSAT / Process Development
0%
Engineering / Automation / Digital
0%
Quality / Compliance / Validation
0%
Supply Chain / Planning
0%
Strategy / Continuous Improvement
0%
Target Attendee Companies
Big Pharma
Biopharma
CDMOs

Targeted Attendees List

View Expanded List
SPONSORSHIP OPPORTUNITIES
Who Should Sponsor?

EPCMV Firms

Design and build partners for next-gen facilities.

Bioprocessing Equipment

Vendors of bioreactors, skids, and single-use systems.

Industry 4.0 Providers

Digital Twin, MES, and AI process control solutions.

QMS Software

Platforms for digital quality, data integrity, and remote oversight.

Process Intensification

Perfusion and continuous processing specialists.

Sponsorship_bwd2026_icon__0004

Thought Leadership Speaking

Sponsorship_bwd2026_icon__0003

Panel Participation

Sponsorship_bwd2026_icon__0002

Solution Showcases

Sponsorship_bwd2026_icon__0001

Engagement and Visibility Opportunities

Sponsorship_bwd2026_icon__0006

Branding and Digital Visibility

Sponsorship_bwd2026_icon__0000

Exclusive Networking

TESTIMONIALS
Speaker Headshot BWD2026 Heiner Apeler 2
Dr Heiner Apeler
VP Head of Biologics Development
Bayer Germany

The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.

BioOut2026_SPEAKER_John Bridgeman
John Bridgeman
CSO
Immunokey UK

Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey’s development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal. 

Speakers_photo_bwd_website_Dennis-Stelljes
Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS Switzerland

 Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I’m excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity! 

Speaker Headshot BWD2026 Andrew Kelly 2
Dr Andrew Kelly
Director, Manufacturing Technology
BMS Ireland

Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators 

Speakers_photo_bwd_website_Thomas-Villiger
Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW Switzerland

A fantastic deep dive into the DACH region’s CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together. 

Brian O'Connor | VP Global Quality, Orchard Therapeutics, UK
Brian O'Connor
VP Global Quality
Orchard Therapeutics UK

Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees. 

Alvaro Avivar-Valderas | Associate Director - Cell Therapy Technology & Product Engine, Takeda, Spain
Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda Spain

Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!

Speaker Headshot BWD2026 Steffen Schulze 2
Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche Switzerland

I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants. 

merck200
Terry Gray
Field Marketing Manager
Merck

I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.

BioUK2026_SPEAKER_Dr Warren Roche
Warren Roche
Senior Statistical Expert
Sanofi Ireland

Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event 

BWD2026 Website Headshot Speaker Michael Inglis 2
Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease Ireland

Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event.

I hope we have opportunity to connect again in the future.

Speaker Headshot BWI2026 Shada Warreth 2
Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT Ireland

 Well done on a very informative and successful event.

 

TICKETS
free_ticket_mockup_london_biomanuk26_bp_website.4564ec01ff01
From £699 + VAT
free_ticket_mockup_london_biomanuk26_ssp_website.144dadbd20be
From £2895 + VAT

VENUE

Radisson Blu Hotel, London Heathrow

140 Bath Road, Harlington, Hayes UB3 5AW, UK
Getting There Accommodation Options View the Floorplan

Travel Options

Travel options Radisson Blu Hotel, London Heathrow 140 Bath Road, Hayes, Middlesex, UB3 5AW
We look forward to welcoming you to our event at the Radisson Blu Hotel, conveniently located just minutes from Heathrow Airport. Please find travel guidance below to help you plan your journey. 
subway.286a621e9981

By London Underground

Take the London Underground Piccadilly Line toward Heathrow Airport.

  • Alight at Heathrow Terminal 2 & 3 Underground Station
  • From the station, the hotel is a short taxi or bus journey away

Estimated travel time: 45–60 minutes from central London.

bus.092fa764c07e

From Heathrow Airport

The hotel is located along Bath Road, with regular bus services connecting all terminals.

  • Local bus routes: 105, 111, 140, 285
  • Hotel Hoppa shuttle service also available
  • Alight on Bath Road, a short walk from the hotel

Estimated travel time: 10–20 minutes

taxi_2.75bc650d90cf

Taxi or Ride-Hailing

Taxis and ride-hailing services are readily available at all Heathrow terminals.

Estimated travel time: 5–10 minutes Estimated cost: £10–£20

car.e22d1548067f

By Car

The hotel is easily accessible by road:

  • Address: 140 Bath Road, Hayes, Middlesex, UB3 5AW
  • Located just off the M4 motorway
On-site parking is available at the hotel
train_2.c46ac37e7110

From Other UK Cities

For guests travelling from outside London:

  • Arrive at London Paddington Station
  • Continue via:
    • Heathrow Express (fastest option), or
    • Elizabeth line (cost-effective alternative)
  • Transfer to bus or taxi for the final leg

Accommodation Options

Explore recommended hotels near the venue.

Exclusive delegate hotel rate

Please note: the conference registration fee does not include hotel accommodation or travel expenses.

IMAPAC has secured an exclusive discounted room rate for conference delegates. Use one of the booking options below and quote the conference block code where applicable.

Please complete your booking by 03 October 2026 to secure the discounted conference rate. Bookings made after the cut-off date are subject to hotel availability and may be charged at the prevailing room rate.

Standard Double Room

  • Single occupancy£129.00
  • Double occupancy£139.00

Rates include full breakfast.

Call the Radisson Blu Hotel, London Heathrow at +44 (0)20 8759 6311 and quote the block code “BIOF021126”.

Option 2 – By Email

Email the Radisson Blu Hotel, London Heathrow Reservations Team at reservations.heathrow@radissonblu.com
and quote the block code “BIOF021126”.

Email Hotel
Radisson Blu Hotel, London Heathrow Venue Hotel Special Rate

Radisson Blu Hotel, London Heathrow

140 Bath Road, Hayes, Middlesex, UB3 5AW
venue for this event

 To book a room at this hotel, please click the button below 

Book a Room
accom 2

London Heathrow Mariott Hotel

Bath Road Heathrow, Airport, Hayes UB3 5AN
4 minute walk from venue

 To book a room at this hotel, please click the button below 

Book a Room
accom 3

Ibis Style London Heathrow Airport

272 Bath Rd, London UB3 5AY
8 minute walk from venue

 To book a room at this hotel, please click the button below 

Book a Room
accom 4

Premier Inn London Heathrow

15 Bath Rd, London TW6 2AB
5 minute drive from venue

 To book a room at this hotel, please click the button below 

Book a Room
Event venue floorplan

Virtual Tour of Commonwealth Suite Virtual Tour of the Atrium Virtual Tour of Royal Suite
Please find the booth allocation in the table below.
3 Briggs of Burton 4 Alfa Laval 7a MabPlex 7b Greenfield Global 8 BSP Pharmaceuticals 11 QuickSTAT 14 AsTec Chemicals 17 Unchained Labs 18 Kemwell Biopharma 19 Inprocess LSP